Table 2.

Summary of results of Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: A pilot randomized controlled trial. Am J Obstet Gynecol. 2016. (ref)

	10 mg cohort
	Placebo (N= 10)	Pravastatin (N= 10)
Use of low-dose aspirin	3 (30)	2 (20)
Heartburn	3 (30)	4 (40)
Musculoskeletal pain	1 (10)	4 (40)
Maternal, fetal, or infant death	0	0
Rhabdomyolysis	0	0
Liver injury	0	0
Myopathy (weakness without increase in CK)	0	0
Congenital anomalies	2	2
Preeclampsia (any)	4 (40)	0
Preeclampsia with severe features	3 (30)	0
Gestational age at delivery (wks)	36.7± 2.1	37.7± 0.9
Indicated preterm delivery < 37 weeks	5 (50)	1 (10)
Indicated preterm delivery < 34 weeks	1(10)	0 (0)
Total cholesterol at 34– 37 weeks (mg/dl)	252 ± 27	207 ± 31
LDL cholesterol at 34–37 weeks (mg/dl)	130.8 ± 46.7	90.4 ± 21.9
Birth weight (g)	2,877±630	3,018± 260
Highest level of care routine nursery	5 (50)	8 (80)
NICU length of stay ≥ 48 hours	3 (30)	0